Though safe, nilotinib does not show promise for benefit for Parkinson's disease

(Northwestern University) The Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson's drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson's but does not exert a clinically meaningful benefit or biological effect to benefit those with Parkinson's disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Contributors : Ling Li ; Xin HeSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe want to obtain FLT3-ITD gene signature. To do so, we transduced CB CD34+ cells with mock or FLT3-ITD vectors and performed RNA sequencing (RNA-Seq).Two Groups: Group1: CB CD34+ cells transduced with mock vector; Group2: CB CD34+ cells transduced with FLT3-ITD vector;
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Elizabeth Ostrander ; Grant A ChallenSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusEpigenetic modifying enzymes DNMT3A and TET2 are recurrently mutated in hematological disorders despite possessing opposing biochemical functions in the DNA methylation processes. Using conditional ablation, we show these contrasting genotypes result in different functional effects in hematopoietic stem cells (HSCs). Loss of Dnmt3a bestows enhanced self-renewal on HSCs in serial, competitive repopulation assays while Tet...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing Mus musculus Source Type: research
Publication date: Available online 31 March 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Nada Alhazmi, Chun-Peng Pai, Aljawharah Albaqami, Han Wang, Xuan Zhao, Minyue Chen, Po Hu, Shuang Guo, Kyle Starost, Omid Hajihassani, Masaru Miyagi, Hung-Ying Kao
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson's disease, a new study finds. In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson's disease, a new study finds. In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Nilotinib hydrochloride, an Abelson tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, has been in the neurology news since the results of the open-label, phase 1 study in a small group of patients with advanced Parkinson disease (PD) and dementia with Lewy bodies was reported at the Society for Neuroscience in Chicago in October 2015. The extensive media coverage that followed, supported by videos of nilotinib-treated participants getting up and walking from their wheelchairs, suggested that disease modification in PD was within reach with this drug. The corresponding publication documented that,...
Source: JAMA Neurology - Category: Neurology Source Type: research
Objective: To examine the effects of lower doses (
Source: Neurology - Category: Neurology Authors: Tags: Redefining Parkinson ' s Disease: Novel Approaches to Understanding Its Mechanisms and Developing Treatments Data Blitz Presentations Source Type: research
Objectives: To examine the effects of Nilotinib on CSF biomarkers in PD with dementia and LBD patients. Background: PD involves death of dopamine producing neurons in the Substantia Nigra pars compacta. Alpha-Synuclein accumulation into Lewy bodies (LBs) is the pathological hallmark of Synucleinopathies. As PD progresses, p-Tau and beta-amyloid (Abeta) pathologies coincide with the onset of dementia. Pre-clinical data indicate that the tyrosine kinase Abl (Abelson) inhibitor Nilotinib penetrates the brain and induces autophagic clearance of alpha-Synuclein, p-Tau and Abeta. Design and methods: Nilotinib is FDA-approved for...
Source: Neurology - Category: Neurology Authors: Tags: Redefining Parkinson ' s Disease: Novel Approaches to Understanding Its Mechanisms and Developing Treatments Poster Presentations Source Type: research
Objective: To examine the effects of lower doses (
Source: Neurology - Category: Neurology Authors: Tags: Movement Disorders: Parkinson ' s Disease Clinical Trials and Therapeutics Source Type: research
Objectives: To examine the effects of Nilotinib on CSF biomarkers in PD with dementia and LBD patients. Background: PD involves death of dopamine producing neurons in the Substantia Nigra pars compacta. Alpha-Synuclein accumulation into Lewy bodies (LBs) is the pathological hallmark of Synucleinopathies. As PD progresses, p-Tau and beta-amyloid (Abeta) pathologies coincide with the onset of dementia. Pre-clinical data indicate that the tyrosine kinase Abl (Abelson) inhibitor Nilotinib penetrates the brain and induces autophagic clearance of alpha-Synuclein, p-Tau and Abeta. Design and methods: Nilotinib is FDA-approved for...
Source: Neurology - Category: Neurology Authors: Tags: Movement Disorders: Parkinson ' s Disease Clinical Trials and Therapeutics Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | International Medicine & Public Health | Leukemia | Nilotinib | Parkinson's Disease | Study | Tasigna